

Pancreatic Cancer Therapeutics and Diagnostics Market Report by Type (Diagnostics, Treatment), Application (Hospitals, Clinics, and Others), and Region 2024-2032

Market Report | 2024-04-08 | 140 pages | IMARC Group

AVAILABLE LICENSES:

- Electronic (PDF) Single User \$3899.00
- Five User Licence \$4899.00
- Enterprisewide License \$5899.00

Report description:

The global pancreatic cancer therapeutics and diagnostics market size reached US\$ 4.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US\$ 7.6 Billion by 2032, exhibiting a growth rate (CAGR) of 6.51% during 2024-2032. The burgeoning healthcare industry, rising prevalence of pancreatic cancer, and the escalating demand for chemotherapy to kill pancreatic cancer cells represent some of the key factors driving the market.

Pancreatic cancer therapeutics and diagnostics are medical procedures used to diagnose pancreatic cancer and provide treatment. These therapeutics and diagnostics comprise ultrasound, computerized tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET) scans. They rely on an endoscopic ultrasound (EUS) that uses an ultrasound device to produce images of the pancreas from inside the abdomen. They help in monitoring the location of the tumor due to an uncontrollable growth of cells in the pancreas. They assist in performing a biopsy to remove a small sample of tissue for examination under a microscope. They also aid in laboratory investigations, such as a complete blood count (CBC), liver enzyme tests for biliary obstruction, and fasting glucose and glycated hemoglobin (HbA1C) tests. As a result, pancreatic cancer therapeutics and diagnostics find applications in hospitals and specialty centers across the globe.

Pancreatic Cancer Therapeutics and Diagnostics Market Trends:

At present, the rising prevalence of pancreatic cancer due to the increasing geriatric population and excessive smoking habits among the masses represents one of the key factors supporting the growth of the market. Besides this, there is an increase in the development of molecular biology, drugs, and diagnostic technology around the world. This, along with the thriving healthcare industry, is currently propelling the growth of the market. In addition, the escalating demand for chemotherapy to kill pancreatic cancer cells by preventing them from growing and dividing is positively influencing the market. Moreover, governing agencies of several countries are extensively investing in pancreatic cancer clinical trial testing and deoxyribonucleic acid (DNA) repair inhibitors combined with chemotherapy. They are also focusing on enhancing the growth of pancreatic cancer therapeutics and diagnostics by approving drugs in the clinical phase. Apart from this, key players operating in the industry are introducing a

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

humanized monoclonal antibody that promotes the anti-tumor immune response for treating esophageal and gastroesophageal junction and pancreatic cancer. They are also developing and introducing kit-based testing to detect pancreatic cancer by determining BRCA1 and BRCA2 variants and assessing genomic instability, which is projected to contribute to the growth of the market in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global pancreatic cancer therapeutics and diagnostics market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on type and application.

Type Insights:

- Diagnostics
 - Imaging
 - Biopsy
 - Endoscopic Ultrasound
 - Others
- Treatment
 - Targeted Therapies
 - Chemotherapy
 - Surgery
 - Others

The report has provided a detailed breakup and analysis of the pancreatic cancer therapeutics and diagnostics market based on the type. This includes diagnostics (imaging, biopsy, endoscopic ultrasound, and others) and treatment (targeted therapies, chemotherapy, surgery, and others). According to the report, treatment accounted for the largest market share.

Application Insights:

- Hospitals
- Clinics
- Others

A detailed breakup and analysis of the pancreatic cancer therapeutics and diagnostics market based on application has also been provided in the report. This includes hospitals, clinics, and others. According to the report, hospitals represented the leading segment.

Regional Insights:

- North America
 - United States
 - Canada
- Asia Pacific
 - China
 - Japan
 - India
 - South Korea

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. According to the report, North America was the largest market for pancreatic cancer therapeutics and diagnostics. Some of the factors driving the North America pancreatic cancer therapeutics and diagnostics market included advancements in diagnostic technologies, emerging therapies and treatment options, increasing healthcare expenditure, and government initiatives and funding.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global pancreatic cancer therapeutics and diagnostics market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies include AstraZeneca plc, F. Hoffmann-La Roche Ltd., Immunovia AB, Novartis AG, Pfizer Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

How has the global pancreatic cancer therapeutics and diagnostics market performed so far and how will it perform in the coming years?

What are the drivers, restraints, and opportunities in the global pancreatic cancer therapeutics and diagnostics market?

What are the key regional markets?

Which countries represent the most attractive pancreatic cancer therapeutics and diagnostics markets?

What is the breakup of the market based on the type?

Which is the most attractive type in the pancreatic cancer therapeutics and diagnostics market?

What is the breakup of the market based on the application?

Which is the most attractive application in the pancreatic cancer therapeutics and diagnostics market?

What is the competitive structure of the global pancreatic cancer therapeutics and diagnostics market?

Who are the key players/companies in the global pancreatic cancer therapeutics and diagnostics market?

Table of Contents:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

1	Preface
2	Scope and Methodology
2.1	Objectives of the Study
2.2	Stakeholders
2.3	Data Sources
2.3.1	Primary Sources
2.3.2	Secondary Sources
2.4	Market Estimation
2.4.1	Bottom-Up Approach
2.4.2	Top-Down Approach
2.5	Forecasting Methodology
3	Executive Summary
4	Introduction
4.1	Overview
4.2	Key Industry Trends
5	Global Pancreatic Cancer Therapeutics and Diagnostics Market
5.1	Market Overview
5.2	Market Performance
5.3	Impact of COVID-19
5.4	Market Forecast
6	Market Breakup by Type
6.1	Diagnostics
6.1.1	Market Trends
6.1.2	Key Segments
6.1.2.1	Imaging
6.1.2.2	Biopsy
6.1.2.3	Endoscopic Ultrasound
6.1.2.4	Others
6.1.3	Market Forecast
6.2	Treatment
6.2.1	Market Trends
6.2.2	Key Segments
6.2.2.1	Targeted Therapies
6.2.2.2	Chemotherapy
6.2.2.3	Surgery
6.2.2.4	Others
6.2.3	Market Forecast
7	Market Breakup by Application
7.1	Hospitals
7.1.1	Market Trends
7.1.2	Market Forecast
7.2	Clinics
7.2.1	Market Trends
7.2.2	Market Forecast
7.3	Others
7.3.1	Market Trends
7.3.2	Market Forecast

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8 Market Breakup by Region

8.1 North America

8.1.1 United States

8.1.1.1 Market Trends

8.1.1.2 Market Forecast

8.1.2 Canada

8.1.2.1 Market Trends

8.1.2.2 Market Forecast

8.2 Asia-Pacific

8.2.1 China

8.2.1.1 Market Trends

8.2.1.2 Market Forecast

8.2.2 Japan

8.2.2.1 Market Trends

8.2.2.2 Market Forecast

8.2.3 India

8.2.3.1 Market Trends

8.2.3.2 Market Forecast

8.2.4 South Korea

8.2.4.1 Market Trends

8.2.4.2 Market Forecast

8.2.5 Australia

8.2.5.1 Market Trends

8.2.5.2 Market Forecast

8.2.6 Indonesia

8.2.6.1 Market Trends

8.2.6.2 Market Forecast

8.2.7 Others

8.2.7.1 Market Trends

8.2.7.2 Market Forecast

8.3 Europe

8.3.1 Germany

8.3.1.1 Market Trends

8.3.1.2 Market Forecast

8.3.2 France

8.3.2.1 Market Trends

8.3.2.2 Market Forecast

8.3.3 United Kingdom

8.3.3.1 Market Trends

8.3.3.2 Market Forecast

8.3.4 Italy

8.3.4.1 Market Trends

8.3.4.2 Market Forecast

8.3.5 Spain

8.3.5.1 Market Trends

8.3.5.2 Market Forecast

8.3.6 Russia

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.3.6.1 Market Trends
- 8.3.6.2 Market Forecast
- 8.3.7 Others
 - 8.3.7.1 Market Trends
 - 8.3.7.2 Market Forecast
- 8.4 Latin America
 - 8.4.1 Brazil
 - 8.4.1.1 Market Trends
 - 8.4.1.2 Market Forecast
 - 8.4.2 Mexico
 - 8.4.2.1 Market Trends
 - 8.4.2.2 Market Forecast
 - 8.4.3 Others
 - 8.4.3.1 Market Trends
 - 8.4.3.2 Market Forecast
- 8.5 Middle East and Africa
 - 8.5.1 Market Trends
 - 8.5.2 Market Breakup by Country
 - 8.5.3 Market Forecast
- 9 Drivers, Restraints, and Opportunities
 - 9.1 Overview
 - 9.2 Drivers
 - 9.3 Restraints
 - 9.4 Opportunities
- 10 Value Chain Analysis
- 11 Porters Five Forces Analysis
 - 11.1 Overview
 - 11.2 Bargaining Power of Buyers
 - 11.3 Bargaining Power of Suppliers
 - 11.4 Degree of Competition
 - 11.5 Threat of New Entrants
 - 11.6 Threat of Substitutes
- 12 Price Analysis
- 13 Competitive Landscape
 - 13.1 Market Structure
 - 13.2 Key Players
 - 13.3 Profiles of Key Players
 - 13.3.1 AstraZeneca plc
 - 13.3.1.1 Company Overview
 - 13.3.1.2 Product Portfolio
 - 13.3.1.3 Financials
 - 13.3.1.4 SWOT Analysis
 - 13.3.2 F. Hoffmann-La Roche Ltd.
 - 13.3.2.1 Company Overview
 - 13.3.2.2 Product Portfolio
 - 13.3.3 Immunovia AB
 - 13.3.3.1 Company Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.3.3.2 Product Portfolio
- 13.3.4 Novartis AG
 - 13.3.4.1 Company Overview
 - 13.3.4.2 Product Portfolio
 - 13.3.4.3 Financials
 - 13.3.4.4 SWOT Analysis
- 13.3.5 Pfizer Inc.
 - 13.3.5.1 Company Overview
 - 13.3.5.2 Product Portfolio
 - 13.3.5.3 Financials
 - 13.3.5.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Pancreatic Cancer Therapeutics and Diagnostics Market Report by Type (Diagnostics, Treatment), Application (Hospitals, Clinics, and Others), and Region 2024-2032

Market Report | 2024-04-08 | 140 pages | IMARC Group

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Electronic (PDF) Single User	\$3899.00
	Five User Licence	\$4899.00
	Enterprisewide License	\$5899.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-26"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com
www.scotts-international.com